Jørgen Buus Lassen

Effector A/S is a Danish company that specializes in creating effective health communication. The private company is based in Copenhagen, Denmark, and has subsidiaries in Norway. The company develop various exciting projects for their clients.

Gudme Raaschou Invest A/S (GRI) is an investment management firm based in Copenhagen, Denmark. GRI is a wholly-owned subsidiary of Gudme Raaschou Asset Management Holding A/S, which is a wholly-owned subsidiary of Gudme Raaschou Bank A/S, and ultimately of Copenhagen-based Gudme Raaschou Holding A/S. The firm administers and distributes the Gudme Raaschou Health Care unit trust, as well as the Gudme Raaschou unit trust, which is composed of several compartments: Nordic Alpha, European Bonds, High Yield and US High Yield. Both unit trusts are managed by their affiliate, Gudme Raaschou Asset Management.

Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.